ArticleNature medicine2011
Trastuzumab resistance: all roads lead to SRC.
Article in Nature medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo.Biological procedures online · 2023Article
- Article
- SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.Breast cancer research : BCR · 2022Review
- Article
- Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.JCI insight · 2021Article
- Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.Nature communications · 2021Article
- Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine.Journal of medicinal chemistry · 2020Article
- Monitoring Src status after dasatinib treatment in HER2+ breast cancer withBreast cancer research : BCR · 2018Article
- Article
- αE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway.Genes & development · 2016Article
- Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.Molecular cancer therapeutics · 2016Article
- p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.Oncotarget · 2016Article
- Article
- Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1).PloS one · 2015Article
- GeneSense: a new approach for human gene annotation integrated with protein-protein interaction networks.Scientific reports · 2014Article
- PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.Journal of translational medicine · 2013Article
- Drugs for solid cancer: the productivity crisis prompts a rethink.OncoTargets and therapy · 2013Article
- Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2012Review
- Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation.Molecular and cellular biology · 2012Article
- Predictive biomarkers: a paradigm shift towards personalized cancer medicine.Nature reviews. Clinical oncology · 2011Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
21475230What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.